Navigation Links
Chembio Presenting at Biotech Conference
Date:1/9/2012

MEDFORD, N.Y., Jan. 9, 2012 /PRNewswire/ -- Chembio Diagnostics, Inc. (OTC.PK: CEMI and OTC.QB: CEMI), which develops, manufactures, markets and licenses point-of-care diagnostic tests, today announced that Lawrence A. Siebert, President and Chief Executive Officer, will present at the Biotech Showcase in San Francisco at approximately 5:30 pm Eastern Time (2:30 pm Pacific Time) on Wednesday, January 11, 2012.  

The conference will be simultaneously webcast over the Internet. Interested investors can access the live audio webcast of the presentation by going to the Biotech Showcase media server at http://www.media-server.com/m/p/xjsxe3aa.    A replay of the webcast, which will be available beginning approximately two hours after the webcast, as well as Chembio's current investor presentation, may be accessed through Chembio's web site, www.chembio.com, and then by clicking on the "Investors/Investor Center" menu (http://phx.corporate-ir.net/phoenix.zhtml?c=121584&p=irol-IRhome). 

About Biotech Showcase

Now in its fourth year, Biotech Showcase will feature corporate presentations by 195 innovative life science companies to an audience of public and private investors, business development executives and professional advisors who are interested in investment opportunities and collaboration. Biotech Showcase takes place during the week of one of the most important healthcare investor conferences which annually attracts thousands of healthcare and life science business executives to San Francisco in a venue located close to the center of action.  To maximize efficiency, all Biotech Showcase participants can schedule one-to-one meetings through EBD Group's online system, partneringONE®.  Public and private investors are always invited to attend on a complimentary basis. Biotech Showcase was co-founded by Demy-Colton Life Science Advisors and EBD Group, two organizations that have a long and successful history building programs that meet the needs of the life science industry.  Visit our website for more information:  www.ebdgroup.com/bts.

About Chembio Diagnostics

Chembio Diagnostics, Inc. develops, manufactures, licenses and markets proprietary rapid diagnostic tests in the growing $7 billion point-of-care testing market. Chembio's two FDA PMA-approved, CLIA-waived, rapid HIV tests are marketed in the U.S. by Alere North America, Inc. (formerly Inverness Medical Innovations, Inc.).  Chembio markets its HIV STAT-PAK® line of rapid HIV tests internationally to government and donor-funded programs directly and through distributors.  Chembio has developed a patented point-of-care test platform technology, the Dual Path Platform (DPP®) technology, which has significant advantages over lateral-flow technologies. This technology is providing Chembio with a significant pipeline of business opportunities for the development and manufacture of new products based on DPP®. Headquartered in Medford, NY, with approximately 140 employees, Chembio is licensed by the U.S. Food and Drug Administration (FDA) as well as the U. S. Department of Agriculture (USDA), and is certified for the global market under the International Standards Organization (ISO) directive 13.485. For more information, please visit: www.chembio.com.

Forward-Looking Statements

Statements contained herein that are not historical facts may be forward-looking statements within the meaning of the Securities Act of 1933, as amended. Forward-looking statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements are estimates only. They reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to Chembio's ability to obtain additional financing and to obtain regulatory approvals in a timely manner, as well as the demand for Chembio's products. Chembio undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in Chembio's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact Chembio's success are more fully disclosed in Chembio's most recent public filings with the U.S. Securities and Exchange Commission.

Company: Contact:
Susan Norcott 631-924-1135 x125 or snorcott@chembio.com

 


'/>"/>
SOURCE Chembio Diagnostics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Resverlogix Presenting at Biotech Showcase
2. Stemline Therapeutics Announces Poster Presenting in vivo and Anti-Cancer Stem Cell Activity of SL-401 against Chronic Myeloid Leukemia (CML) at the 51st Annual Meeting of the American Society of Hematology (ASH)
3. Corgenix Secures $1,750,000 Asset Based Credit Facility Representing Initial Gross Proceeds of $1.109 Million
4. Jesup & Lamont Announces Presenting LifeTech Companies and Former FDA Commissioner at Annual Growth Stock & National Sales Conference
5. IEEE Celebrates Its 125th Anniversary Presenting Emerging, World Changing Technologies During Its Embracing Human Technology Interactions Media Event
6. Selexis SA to Present at Biotech Showcase 2012
7. Saladax Biomedical, Inc. to Present at Biotech Showcase™ 2012
8. SuperNova Diagnostics® to Present at Biotech Showcase™ 2012 During JP Morgan Healthcare Conference January 9 - 12
9. Metamark Genetics Signs Collaboration Agreement on Novel Therapeutic Targets with Janssen Biotech
10. Puma Biotechnology Announces Positive PB272 (Neratinib) Phase II Data at CTRC-AACR San Antonio Breast Cancer Symposium
11. Janssen Biotech, Inc. Announces Collaborative Development and Worldwide License Agreement for Investigational Anti-Cancer Drug, PCI-32765
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016 Andrew D ... http://doi.org/10.17925/OHR.2016.12.01.22 Published recently in ... from touchONCOLOGY, Andrew D Zelenetz , discusses ... care is placing an increasing burden on healthcare ... therapies. With the patents on many biologics expiring, ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... a new line of intelligent tools designed, tuned and optimized exclusively for Okuma ... 12–17 in Chicago. The result of a collaboration among several companies with expertise ...
(Date:6/22/2016)... June 22, 2016 Research and Markets has ... report to their offering. ... 2014 from $29.3 billion in 2013. The market is expected to ... from 2015 to 2020, increasing from $50.6 billion in 2015 to ... forecasts during the forecast period (2015 to 2020) are discussed. As ...
(Date:6/22/2016)... 2016   ViaCyte, Inc. , a privately-held regenerative ... replacement therapy for the treatment of diabetes in clinical-stage ... Meeting.  ISSCR 2016, the Global Stem Cell Event, is ... in San Francisco.    ... follows:Event: , Focus Session: Tools for Basic and Applied ...
Breaking Biology Technology:
(Date:4/28/2016)... , April 28, 2016 First quarter 2016: ... up 966% compared with the first quarter of 2015 ... SEK 589.1 M (loss: 18.8) and the operating margin was 40% ... 0.32) Cash flow from operations was SEK 249.9 M ... revenue guidance is unchanged, SEK 7,000-8,500 M. The operating ...
(Date:4/15/2016)... CHICAGO , April 15, 2016  A ... companies make more accurate underwriting decisions in a ... offering timely, competitively priced and high-value life insurance ... health screenings. With Force Diagnostics, rapid ... and lifestyle data readings (blood pressure, weight, pulse, ...
(Date:3/31/2016)...   LegacyXChange, Inc. ... LegacyXChange is excited to release its first ... be launched online site for trading 100% guaranteed authentic ... also provide potential shareholders a sense of the value ... industry that is notorious for fraud. The video is ...
Breaking Biology News(10 mins):